The odds of eczema are increased with greater exposure to fine particulate matter of diameter ≤2.5 μm (PM2.5).

People are also more likely to struggle with flare ups when air quality is considered 'moderate' - typically seen in the ...

A trio of risk factors not only increase your risk of stroke, but they also raise the odds that such a stroke will be ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Cold sores, sore throats, migraines and conjunctivitis are among the conditions which will no longer be treated on the NHS by ...

Anzupgo is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Switzerland specifically for moderate to ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Eczema affects an estimated 20 per cent of children and 11 per cent of adults in Singapore. In its moderate to severe form, ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.